Navigation Links
Change in PSA level does not predict prostate cancer
Date:2/24/2011

NEW YORK, February 24, 2011 Researchers at Memorial Sloan-Kettering Cancer Center have found that change in PSA levels over time known as PSA velocity is a poor predictor of prostate cancer and may lead to many unnecessary biopsies. The new study of more than 5,000 men was published online February 24 in the Journal of the National Cancer Institute. Andrew Vickers, PhD, Associate Attending Research Methodologist in the Department of Epidemiology and Biostatistics and lead author said, "We have found no evidence to support the recommendation that men with a high PSA velocity should be biopsied in the absence of other indications. In other words, if a man's PSA has risen rapidly in recent years, there is no cause for concern if his total PSA level is still low and his clinical exam is normal."

Prostate cancer is the most common cancer among American men and the second leading cause of cancer deaths in men, according to the American Cancer Society. While PSA screening is widely used for the early detection of prostate cancer, it is also associated with a high rate of overdiagnosis, which can lead to unnecessary treatment and anxiety. Currently, early detection guidelines of several organizations (the National Cancer Center Network and the American Urological Association) recommend that men with a rapid rise in PSA or a high PSA velocity have a surgical biopsy for prostate cancer, even if there are no other indicators that cancer may exist. Those indicators could be an elevated baseline PSA or a positive digital rectal exam (DRE).

This study's population came from the Prostate Cancer Prevention Trial. Five thousand five hundred and nineteen men aged 55 years and older with no previous prostate cancer diagnosis, normal DRE, and a baseline PSA of 3.0 ng/mL or less were randomly assigned to finasteride a drug commonly used to treat enlargement of the prostate gland, more commonly referred to as BPH, or benign prostatic hypertrophy or placebo for seven years. This particular study focused on the men in the placebo group. The men were followed with yearly PSA tests, with biopsy recommended for men with a PSA higher than 4.0 ng/mL. After seven years, all men who were not diagnosed with prostate cancer were asked to consent to an end-of-study biopsy.

Dr. Vickers and colleagues found no important association between PSA velocity and biopsy outcome after adjusting for risk factors such as age, race, and PSA levels. PSA alone was a much better predictor of biopsy outcome than PSA velocity.

According to Peter T. Scardino, MD, Chair of the Department of Surgery, "This study should change practice. We have previously published papers determining that PSA naturally varies from month to month and have urged men whose PSA suddenly rises to wait six weeks and repeat the test before agreeing to a needle biopsy. This new study in a large population of men provides even stronger evidence that using changes in PSA as a basis for recommendation for biopsy leads to many more unnecessary biopsies and does not help to find the more aggressive cancers that we want to find and treat." Dr. Scardino added that "men should be cautious before rushing into a biopsy for minor variations in their PSA level."


'/>"/>

Contact: Courtney DeNicola Nowak
denicolc@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. Physical Changes in Brain Linked to Altered Spirituality
2. Whitemark Homes Inc. Announces Change of Auditors and Additional Corporate Information
3. Apptix Signs 100,000 Seat Hosted Exchange Email Contract
4. Northern California Cancer Center Changes Name to Cancer Prevention Institute of California
5. Tyco International Announces Exchange Rate for Quarterly Dividend
6. MARC Coalition Applauds Agencys Alert Regarding Delay in Data Exchange Deadline
7. Medicare Advantage Members May Make Changes During Open Enrollment
8. Clearwave Corporation Creates Healthcare's First Patient-Facing Network Exchange
9. CMS Watch Changes Name to The Real Story Group
10. Changes during menopause increases risk of heart disease and stroke
11. Access to Mammograms Drops After Guidelines Change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Lake Orion, Michigan (PRWEB) , ... May 24, 2016 , ... ... Aroma Yoga. , The Yoga practice enhanced with Young Living Essential Oils, taught ... 6:30pm - 8pm at the Lake Orion location. Yoga Flow is 6:30pm - 7:15pm ...
(Date:5/24/2016)... ... ... Controlling and maintaining the home’s water heater just got infinitely easier, more convenient ... , a first-of-its-kind system that enables remote and convenient control of a water heater ... HVAC systems, Aquanta gives users a much more efficient, versatile way to use (or ...
(Date:5/24/2016)... ... May 24, 2016 , ... Aloria Health ... To Begin In June , Aloria Health, specializing in a re-imagined, client-oriented approach ... Aloria Milwaukee, its first treatment facility for outpatient, day treatment and residential care. ...
(Date:5/24/2016)... ... 2016 , ... The old expression “a pain in the neck” takes on ... misunderstood, whiplash should be swiftly diagnosed and treated if those affected want to quickly ... Spine Center . , So named because of the whip-like, rapid back-and-forth neck ...
(Date:5/24/2016)... DC (PRWEB) , ... May 24, 2016 , ... ... month on the successful implementation of protocols designed to reduce bleeding complications from ... Society for Cardiovascular Angiography and Interventions (SCAI) in Orlando, FL, document a 40% ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... 23, 2016 Global Paclitaxel Market ... profiles 12 companies and the Paclitaxel analysis in this ... the industry and its players. This is ... nature, details the current state of the industry while ... classifications, applications and industry chain structure. The Paclitaxel market ...
(Date:5/23/2016)... 23, 2016 According to ... Development, Growth and Demand Forecast to 2022 - ... by Application (Drug Discovery and Development, Proteomics, Clinical ... Life Science and Biotechnology, Academic and Research Institute, ... the global mass spectrometry market was ...
(Date:5/23/2016)... 2016 Non-invasive diagnostic test realizes ... diseases; ,Technology to be presented at Yissum’s booth, at ... Development Company of the Hebrew University of Jerusalem ... with Aurum Ventures MKI, the technology investment arm of ... diagnostic approach for early detection of multiple diseases by ...
Breaking Medicine Technology: